Table of Contents
Index
- 2008 Sales of VEGF/R Antagonists
- VEGF-R Agonists
- Cardiovascular Applications
- Neurological Applications
- VEGF and VEGF-R Antagonists in Ophthalmology
- VEGF and VEGF-R Antagonists in Oncology
- Avastin Pipeline
- Biologics as VEGF and VEGF-R Antagonists
- Small Molecules as VEGF RTK Inhibitors
- Sutent Pipeline
- Nexavar Pipeline
- Selective VEGF RTK Inhibitors
- Dual Target VEGF RTK Inhibitors
- Triple Target VEGF RTK Inhibitors
- Multi-Target VEGF RTK Inhibitors
- Overview on RTK Inhibion Profiles of VEGF-R Inhibitors
- Corporate VEGF and VEGF-R Agonists and Antagonists
- About La Merie
Corporate VEGF/R Agonist and Antagonist R&D Pipelines
- Accelera
- ACT Biotech
- Advenchen Laboratories
- Affitech
- Allergan
- Allostera Pharma
- Alnylam Pharmaceuticals
- Amgen
- Ark Therapeutics
- AstraZeneca
- Attenuon
- Aveo Pharmaceuticals
- Bayer Schering-Pharma
- Bio-Sidus
- Boehringer Ingelheim
- Bristol-Myers Squibb (BMS)
- Cephalon
- Chugai
- Circadian
- CSL
- Cyclacell Pharmaceuticals
- DxS
- Edwards Lifesciences
- Eisai
- Eli Lilly
- Epitomics
- Ethycal Oncology Sciences (EOS)
- Exelixis
- Eyetech
- Genentech
- GlaxoSmithKline (GSK)
- Jubilant Innovation
- Kringle Pharmaceuticals
- Methylgen
- Millennium
- Molecular Partner
- Nanogen Biopharmaceuticals
- Neovacs
- NeuroNova
- Neurotech
- Novartis
- Onyx Pharmaceuticals
- Opko
- OSI Pharmaceuticals
- Oxford BioMedica
- Pepscan Systems
- Pfizer
- Pieris
- PTC Therapeutics
- Regeneron Pharmaceuticals
- Roche
- Sangamo Biosciences
- Sanofi-aventis
- Schering
- SibTech
- Sirna Therapeutics
- Sopherion Therapeutics
- Symphony Evolution
- Takeda Pharmaceutical
- Targa Therapeutics
- Tekmira
- Telik
- Tigris Pharmaceuticals
- Toolgen
- Trophogen
- VasGene
- ZymoGenetics
|
Related Report
|
View Cart
